Current Report Filing (8-k)
2021年8月19日 - 2:38AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of
1934
Date of
Report (Date of earliest event reported): August 18,
2021
AMERICAN BIO MEDICA
CORPORATION
(Exact
name of registrant as specified in its charter)
New
York
|
0-28666
|
14-1702188
|
(State or other
jurisdiction of incorporation)
|
(Commission File
Number)
|
(IRS Employer
Identification Number)
|
122 Smith Road, Kinderhook,
NY
|
12106
|
(Address of
principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: 518-758-8158
Not applicable
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see
General Instruction A.2.
below):
☐ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
☐ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title of each
class
|
Trading
Symbol(s)
|
Name of each exchange on which
registered
|
Common
|
ABMC
|
OTC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging
growth compan
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act.
ITEM 2.02
RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On
August 18, 2021 American Bio Medica Corporation (the "Company")
announced financial results for the quarter ended June 30, 2021. A
copy of the press release announcing the Company’s results
(the "Press Release") is attached hereto as Exhibit 99.1 and is
incorporated by reference in this Item 2.02. The Press Release is
available on the Company’s website. The information provided
in Item 2.02 of this report, including Exhibit 99.1, shall be
deemed to be “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended.
The
Company also expects to file its Form 10-Q on August 18,
2021.
ITEM 9.01
FINANCIAL STATEMENTS AND EXHIBITS
(d)
99.1
The
Press Release
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
AMERICAN BIO MEDICA CORPORATION (Registrant)
|
|
|
|
|
|
Dated:
August
18 2021
|
By:
|
/s/ Melissa A.
Waterhouse
|
|
|
|
Melissa
A. Waterhouse
|
|
|
|
Chief Executive
Officer
(Principal Executive
Officer)
|
|
|
|
|
|
American Bio Medica (CE) (USOTC:ABMC)
過去 株価チャート
から 11 2024 まで 12 2024
American Bio Medica (CE) (USOTC:ABMC)
過去 株価チャート
から 12 2023 まで 12 2024
Real-Time news about American Bio Medica Corporation (CE) (その他OTC): 0 recent articles
その他のAmerican Bio Medica Corpニュース記事